BMS and Ono expand deals for Orencia and Phase II anticancer antibody
This article was originally published in Scrip
Bristol-Myers Squibb and Ono Pharmaceuticals have agreed to expand their existing agreements for two products, giving BMS broader rights to an investigational anticancer antibody and granting Ono Japanese co-commercialisation rights to BMS's arthritis drug, Orencia (abatacept).
You may also be interested in...
The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.
From the latest COVID-19 advances to the emergence of game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.